RNA (RNA)

Financial Metrics & Valuation Analysis

Enterprise Valuation (TTM)

Enterprise Value-$71.02M
EV / Sales-3.47
EV / EBITDA1.10
EV / Operating Cash Flow1.41
EV / Free Cash Flow1.33

Return Metrics (TTM)

Return on Equity (ROE)-29.67%
Return on Assets (ROA)-22.13%
Return on Invested Capital (ROIC)-23.91%
Return on Capital Employed (ROCE)-24.15%

Yield Metrics

Earnings Yield-33.33%
Free Cash Flow Yield-27.49%

Balance Sheet Strength

Net Debt / EBITDA4.12
Current Ratio13.04
Working Capital$263.66M
Tangible Asset Value$234.10M
Net Current Asset Value$227.31M

Working Capital Efficiency

Days Sales Outstanding267.15
Days Payables Outstanding1950.70
Operating Cycle (Days)267.15
Cash Conversion Cycle-1683.54

Capital Allocation

CapEx / Revenue14.53%
CapEx / Operating Cash Flow-5.91%
R&D / Revenue171.53%
SG&A / Revenue246.43%

Fiscal Year 2025 Ratios

Audited annual results as of 2025-12-31

Margins

Gross Profit Margin100.00%
Operating Margin-412.58%
Net Profit Margin-411.88%

Solvency

Debt / Equity0.02
Quick Ratio6.53
Cash Ratio6.46

Per Share

Revenue / Share$1.09
FCF / Share-$2.49
PE Ratio-3.29